Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Prostatic Neoplasms 53Lymphoma 44Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Follicular 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 22Lymphoma, Non-Hodgkin 22Multiple Myeloma 19Leukemia 17Burkitt Lymphoma 13Hodgkin Disease 12Lymphoma, Mantle-Cell 10Neoplasms 8Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, B-Cell, Marginal Zone 8Lymphoma, Large-Cell, Anaplastic 7Neoplasms, Plasma Cell 6Neoplasm Metastasis 6Lymphoma, T-Cell, Peripheral 6Recurrence 4Leukemia, Lymphocytic, Chronic, B-Cell 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pain 3Lymphoma, B-Cell 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Leukemia, Biphenotypic, Acute 2Disease 2

Interventions

Magnetic Resonance Spectroscopy 3Prednisone 2Positron-Emission Tomography 2Lenalidomide 2Injections 2Dexamethasone 2Cyclophosphamide 2technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid) 1obinutuzumab 1lortalamine 1fluciclovine F-18 1Vindesine 1Vincristine 1Transplantation, Autologous 1Thalidomide 1Rituximab 1Mitomycin 1Melphalan 1Doxorubicin 1Diagnosis 1Bleomycin 13-Iodobenzylguanidine 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Disease × Prednisone × Clear all
NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT01659099 2018-03-07

GAINED

The Lymphoma Academic Research Organisation

Phase 3 Terminated
671 enrolled
Lymphoid

Disease, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡